Article info

Original research
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity

Authors

  1. Correspondence to Dr Thomas R Malek; tmalek{at}med.miami.edu
View Full Text

Citation

Hernandez R, LaPorte KM, Hsiung S, et al
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity

Publication history

  • Accepted August 1, 2021
  • First published September 2, 2021.
Online issue publication 
September 02, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.